# TLR3 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - TLR3 is a pattern recognition receptor localized to endosomes that specifically detects double-stranded RNA (dsRNA), a hallmark of viral replication and endogenous damage-associated molecular patterns. Upon binding dsRNA, TLR3 signals exclusively through the TRIF adaptor protein, initiating a cascade that culminates in the production of type I interferons (IFNs) and pro-inflammatory cytokines, crucial for antiviral immunity. - The human TLR3 gene is located on chromosome 4q35.1 and encodes a type I transmembrane glycoprotein with a leucine-rich repeat (LRR) ectodomain for ligand binding and a cytoplasmic Toll/interleukin-1 receptor (TIR) domain for signal transduction. Genetic variations, such as the L412F (rs3775291) and P554S (rs3775290) SNPs, are associated with altered susceptibility to viral infections, autoimmune diseases, and cancer. - TLR3 activation triggers a TRIF-dependent signaling pathway involving NF-κB and IRF3/7 activation, leading to the transcription of pro-inflammatory cytokines (e.g., TNF-α, IL-6) and type I IFNs (e.g., IFN-β). This pathway also mediates non-transcriptional effects like autophagy and apoptosis, with cell-type-specific functions in neuroinflammation, respiratory diseases, and cancer progression. - Dysregulation of TLR3 signaling is implicated in various pathologies, including severe viral encephalitis (e.g., HSV-1, EV71) due to rare loss-of-function mutations, and increased susceptibility to influenza and hepatitis infections due to common polymorphisms. Conversely, TLR3 can act as a tumor suppressor in some cancers, while its agonists like poly(I:C) are explored as immunotherapeutics and vaccine adjuvants. --- ## Executive Summary & Key Metadata Toll-like Receptor 3 (TLR3) is a germline-encoded pattern recognition receptor (PRR) of the innate immune system that specializes in the detection of double-stranded RNA (dsRNA), a molecular signature associated with viral replication and certain endogenous RNA species released during tissue damage. As a type I transmembrane glycoprotein, TLR3 is predominantly localized to endosomal compartments where it surveys the lumen for nucleic acid ligands. Upon engagement with dsRNA, TLR3 initiates a signaling cascade through the sole adaptor protein TIR-domain-containing adapter-inducing interferon-β (TRIF/TICAM1), culminating in the activation of type I interferons (IFNs), pro-inflammatory cytokines, and chemokines. This pathway is fundamental to antiviral immunity, but its dysregulation has been implicated in a spectrum of pathologies ranging from autoimmune diseases and neuroinflammation to cancer progression and metastasis. The human TLR3 gene is located on chromosome 4q35.1 and encodes a protein of 904 amino acids. Its structure is characterized by an extensive extracellular leucine-rich repeat (LRR) domain responsible for ligand binding, a single transmembrane helix, and a cytoplasmic Toll/interleukin-1 receptor (TIR) domain essential for signal transduction. Genetic variation in TLR3, particularly non-synonymous single nucleotide polymorphisms (SNPs) such as rs3775291 (L412F) and rs3775290 (P554S), has been extensively studied for associations with susceptibility to viral infections, autoimmune conditions, and multiple cancer types. The clinical significance of TLR3 extends to its role as a therapeutic target, with synthetic dsRNA analogs like polyinosinic:polycytidylic acid (poly(I:C)) and its derivatives being explored as vaccine adjuvants and immunotherapeutic agents. | **Metadata Field** | **Value** | | :--- | :--- | | **HGNC Symbol** | TLR3 | | **UniProt Accession** | O15455 | | **Representative PDB ID** | 1ZIW (human TLR3 ectodomain) | | **Chromosomal Locus** | 4q35.1 (GRCh38: chr4:186,069,788-186,088,073) | | **Primary Molecular Function** | dsRNA sensing; activation of TRIF-dependent innate immune signaling | | **Disease & Pathology Associations** | Viral encephalitis (HSV-1, EV71, TBEV), influenza severity, chronic hepatitis B/C, hepatocellular carcinoma, breast cancer, prostate cancer, head and neck cancer, type 1 diabetes, systemic lupus erythematosus, rheumatoid arthritis, Parkinson's disease, schizophrenia, myocardial infarction, asthma/COPD exacerbations | ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Location and Gene Structure The human TLR3 gene is mapped to the long arm of chromosome 4 at cytogenetic band q35.1. The reference genome assembly (GRCh38) places the gene between genomic coordinates 186,069,788 and 186,088,073 on the plus strand. The gene spans approximately 18.3 kilobases (kb) of genomic DNA and is composed of five exons, a structure that is conserved across mammalian species [1]. The intron-exon architecture is critical for the regulation of TLR3 expression, with the coding sequence distributed across exons 2 through 5. Exon 1 is non-coding and contributes to the 5' untranslated region (5' UTR), which contains multiple regulatory elements. The promoter region of TLR3 lacks a canonical TATA box but is rich in GC content, a feature common to housekeeping and inducible immune genes. This promoter architecture allows for basal expression in a wide array of cell types while permitting rapid transcriptional upregulation upon stimulation. Several transcription factor binding sites have been identified within the proximal promoter, including consensus sequences for interferon regulatory factors (IRFs), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and signal transducer and activator of transcription (STAT) proteins. These elements are essential for the robust induction of TLR3 expression following viral infection or exposure to type I IFNs [1]. ### 1.2 Promoter Architecture and Epigenetic Regulation The transcriptional regulation of TLR3 is a dynamic process that integrates developmental cues and environmental stimuli. Studies utilizing reporter assays and chromatin immunoprecipitation (ChIP) have demonstrated that the TLR3 promoter is responsive to both IRF3 and IRF7, which bind to interferon-stimulated response elements (ISREs) located within 1 kb upstream of the transcription start site (TSS) [1]. This creates a positive feedback loop wherein TLR3 activation leads to IRF3/7 phosphorylation, subsequent nuclear translocation, and enhanced TLR3 transcription, thereby amplifying the innate immune response. Epigenetic mechanisms play a substantial role in the cell-type-specific expression of TLR3. The promoter and enhancer regions are marked by histone modifications, including H3K4me1 and H3K27ac at active enhancers and H3K4me3 at the promoter in TLR3-expressing cells such as monocyte-derived dendritic cells (moDCs) [1]. Conversely, in cells where TLR3 is silenced, the promoter is enriched for the repressive H3K27me3 mark. DNA methylation at CpG islands within the promoter also correlates with transcriptional repression. The differentiation of monocytes into dendritic cells (DCs) is accompanied by a dramatic remodeling of the TLR3 locus, transitioning from a poised to an active chromatin state, which explains the strong upregulation of TLR3 upon DC maturation [1]. ### 1.3 Alternative Splicing and Isoforms While the canonical TLR3 transcript encodes the full-length 904-amino acid protein, alternative splicing events have been reported. A major splice variant involves the retention of intron 3, which introduces a premature stop codon. This variant, often referred to as TLR3-201 (Ensembl transcript ID ENST00000296795.9), is predicted to encode a truncated protein lacking the transmembrane and TIR domains. If translated, this isoform could potentially be secreted and act as a dominant-negative regulator by sequestering dsRNA ligands. However, the physiological relevance of this and other minor splice variants remains under investigation, and most functional studies focus on the canonical isoform. ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The TLR3 protein is a type I integral membrane glycoprotein composed of 904 amino acids. Its domain architecture can be divided into three principal regions: the large N-terminal ectodomain (ECD), a single-pass transmembrane helix, and the C-terminal cytoplasmic TIR domain. The ECD spans approximately residues 1-703 and is responsible for ligand recognition. It adopts a horseshoe-shaped solenoid structure formed by 23 tandem copies of the leucine-rich repeat (LRR) motif. Each LRR is typically 24-29 residues long and contains the conserved consensus sequence LxxLxLxxNxLxxLxxxxFxxLxx. The concave inner surface of the horseshoe is lined with β-strands, while the convex outer surface is composed of α-helices. This arrangement creates a large, solvent-exposed surface area that is ideally suited for protein-ligand interactions. The ECD is heavily glycosylated, with multiple N-linked glycosylation sites that are essential for proper protein folding, trafficking to endosomes, and ligand binding. The transmembrane domain (residues ~704-726) is a hydrophobic α-helix that anchors the receptor to the endosomal membrane. The cytoplasmic TIR domain (residues ~727-904) adopts a globular fold consisting of a central five-stranded parallel β-sheet surrounded by five α-helices. The TIR domain is the signaling hub of the receptor, providing a scaffold for the recruitment of the adaptor protein TRIF via homotypic TIR-TIR interactions. ### 2.2 Structural Basis of Ligand Recognition The binding of dsRNA to the TLR3 ECD is a well-characterized event. Unlike many other TLRs that bind their ligands as monomers, TLR3 dimerizes upon ligand engagement. The crystal structure of the human TLR3 ECD in complex with dsRNA (PDB: 3CIY) revealed that two TLR3 molecules bind to a single dsRNA duplex, with each receptor contacting the sugar-phosphate backbone of the RNA. Two distinct binding sites on the ECD have been identified: a primary site at the N-terminus (LRR-NT) and a secondary site near the C-terminus (LRR-CT). The binding of dsRNA to these sites stabilizes the dimeric form of the receptor, bringing the two TIR domains into close proximity in the cytoplasm, a prerequisite for signal initiation. The specificity of TLR3 for dsRNA is dictated by the geometry of the RNA duplex. TLR3 preferentially binds to dsRNA molecules of at least 40-50 base pairs in length, with a preference for A-form helical geometry. The receptor makes direct contacts with the 2'-hydroxyl groups of the ribose sugars, which distinguishes dsRNA from dsDNA. This structural discrimination ensures that TLR3 does not respond to self-DNA, which is a critical feature for maintaining immune tolerance. ### 2.3 The TIR Domain and Signal Initiation The TIR domain of TLR3 is structurally conserved across the TLR family. It contains three highly conserved sequence motifs: Box 1, Box 2, and Box 3. Box 1 and Box 2 are involved in the recruitment of downstream signaling molecules, while Box 3 is critical for the structural integrity of the domain. Upon ligand-induced dimerization, the TIR domains of the two TLR3 molecules form a symmetric dimer. This dimeric TIR platform serves as a docking site for the TIR domain of TRIF. The interaction between TLR3 and TRIF is mediated by specific charged and hydrophobic residues on the BB-loop of the TLR3 TIR domain, a region that is also a hotspot for pathogenic mutations. > **[Interactive 3D Protein Visualizer: Load TLR3 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15455)** > > Explore the three-dimensional structure of the TLR3 protein. The visualizer allows you to toggle between the full-length protein, the ectodomain, and the TIR domain. Key structural features, including the LRR repeats, glycosylation sites, and the TRIF-binding interface, are highlighted. Use the tool to analyze the spatial arrangement of clinically relevant mutations such as L412F and P554S. ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The TRIF-Dependent Signaling Cascade TLR3 is unique among the TLR family in that it signals exclusively through the adaptor protein TRIF (also known as TICAM1), making it a member of the MyD88-independent signaling pathway. The engagement of TLR3 by dsRNA in the endosome triggers the recruitment of TRIF to the TIR domain. TRIF then serves as a scaffold to assemble a multi-protein signaling complex that branches into two main pathways: the NF-κB pathway and the IRF3/7 pathway. The activation of NF-κB is initiated by the recruitment of the E3 ubiquitin ligase TRAF6 to the N-terminal region of TRIF. TRAF6, in conjunction with the ubiquitin-conjugating enzyme UBC13, catalyzes the synthesis of K63-linked polyubiquitin chains on itself and on target proteins. These ubiquitin chains serve as a platform for the recruitment of the TAK1 kinase complex (TAK1-TAB1-TAB2). TAK1 then phosphorylates and activates the IKK complex (IKKα, IKKβ, NEMO), which in turn phosphorylates IκBα. Phosphorylated IκBα is targeted for proteasomal degradation, freeing NF-κB (p50/p65 heterodimer) to translocate to the nucleus and drive the transcription of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12p40 [2]. Concurrently, the C-terminal region of TRIF recruits the kinases TBK1 and IKKε via the adaptor proteins TRAF3 and TANK. TBK1/IKKε phosphorylate IRF3, leading to its dimerization and nuclear translocation. In the nucleus, IRF3 binds to ISREs in the promoters of type I IFN genes, most notably IFN-β. The production of IFN-β is a hallmark of TLR3 activation and is essential for establishing an antiviral state in neighboring cells [2]. The IFN-β then acts in an autocrine and paracrine manner through the JAK-STAT pathway to induce the expression of hundreds of interferon-stimulated genes (ISGs), including ISG15, ISG20, and Mx1, which collectively inhibit viral replication [3, 4]. ### 3.2 Regulatory Feedback Loops and Negative Regulation The TLR3 signaling pathway is subject to multiple layers of negative regulation to prevent excessive inflammation and immunopathology. One key mechanism involves the protein TRIM8, which acts as a negative regulator by binding to TRIF and blocking its interaction with TBK1, thereby dampening IRF3 activation and IFN-β production [5]. Another regulatory protein, WDFY1, has been shown to be essential for TLR3/4 signaling by facilitating the recruitment of TRIF to the receptor complex [6]. The balance between positive and negative regulators is critical for maintaining immune homeostasis. The adaptor protein MyD88, typically associated with other TLRs, has been shown to play a complex role in TLR3 signaling. While TLR3 does not require MyD88 for its primary signaling, MyD88 can be recruited to the TLR3 complex under certain conditions and modulate the outcome. For instance, MyD88 has been reported to negatively regulate TLR3-mediated IFN-β induction, likely by competing with TRIF for binding sites or by recruiting inhibitory factors [7]. Conversely, a separate study demonstrated that TLR3 activation can induce the expression of endogenous TLR2 ligands via a MyD88-dependent pathway, thereby augmenting the innate immune response [8]. These findings highlight the intricate crosstalk between different TLR signaling modules. ### 3.3 Non-Transcriptional and Cell-Type-Specific Functions Beyond its canonical role in gene induction, TLR3 activation has been linked to non-transcriptional effects, including the induction of autophagy and programmed cell death. In cardiomyocytes, TLR3 signaling contributes to persistent autophagy and heart failure following myocardial infarction [9]. In cancer cells, TLR3 engagement can directly induce apoptosis, a property that is being exploited for therapeutic purposes [10, 11]. The ability of TLR3 to trigger cell death is often dependent on the cellular context and the presence of other signaling inputs, such as p53 [12]. TLR3 is expressed in a wide variety of cell types beyond classical immune cells, including neurons, astrocytes, microglia, bronchial epithelial cells, keratinocytes, hepatocytes, and mesenchymal stromal cells (MSCs). In the central nervous system, TLR3 activation in microglia and astrocytes contributes to neuroinflammation, which has been implicated in the pathogenesis of neurodegenerative diseases and neuropsychiatric disorders [13, 14, 15, 16]. In the lung, TLR3 signaling in bronchial epithelial cells and smooth muscle cells is a key driver of the inflammatory response to rhinovirus infection, contributing to asthma and COPD exacerbations [1, 2, 3]. In MSCs, TLR3 activation modulates their immunomodulatory properties, enhancing their ability to induce regulatory T cells (Tregs) via Notch signaling [4]. ```mermaid sequenceDiagram participant E as "Endosome" participant T3 as "TLR3" participant TRIF as "TRIF" participant TRAF as "TRAF3/6" participant TBK as "TBK1/IKKε" participant IKK as "IKKα/β/γ" participant IRF as "IRF3" participant NF as "NF-κB" participant Nuc as "Nucleus" participant IFN as "IFN-β & Cytokines" E->>T3: dsRNA (viral/endogenous) T3->>T3: Dimerization T3->>TRIF: TIR-TIR interaction TRIF->>TRAF: Recruits TRAF3 & TRAF6 TRAF->>TBK: Activates TBK1/IKKε TRAF->>IKK: Activates IKK complex TBK->>IRF: Phosphorylates IRF3 IKK->>NF: Phosphorylates IκBα (degradation) IRF->>Nuc: IRF3 dimer translocates NF->>Nuc: NF-κB translocates Nuc->>IFN: ISRE/κB promoter activation ``` ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 The L412F Variant (rs3775291) The most extensively studied non-synonymous SNP in TLR3 is rs3775291, which results in a substitution of phenylalanine for leucine at codon 412 (L412F) within the ectodomain. This variant is located in the LRR region and has been shown to impair the trafficking of TLR3 to the endosome and reduce its ability to bind dsRNA, leading to diminished signaling. The L412F variant has been associated with a wide range of clinical phenotypes, reflecting the central role of TLR3 in antiviral immunity and inflammation. In the context of viral infections, the L412F variant has been linked to increased susceptibility to tick-borne encephalitis virus (TBEV) in Russian and Swedish populations [5, 6]. It has also been associated with severe outcomes in patients infected with H7N9 avian influenza and pandemic H1N1 influenza, where it contributes to a cumulative genetic risk when combined with other risk alleles [7]. The variant has been implicated in the natural course of hepatitis B virus (HBV) infection, with studies showing associations with spontaneous HBsAg seroclearance and the risk of developing hepatocellular carcinoma (HCC) [8, 9, 10]. A meta-analysis of TLR3 gene polymorphisms in cancer found that the L412F variant is associated with an increased risk of certain cancers, although the results are heterogeneous across cancer types [11]. The L412F variant has also been investigated in the context of autoimmune and inflammatory diseases. It has been associated with an increased risk of type 1 diabetes mellitus (T1DM) in a Brazilian population [12, 13]. In a Danish cohort, the variant was found to be associated with seronegative rheumatoid arthritis [14]. Furthermore, the variant has been linked to the development of chronic inflammatory conditions such as oral lichen planus [15]. ### 4.2 The P554S Variant (rs3775290) Another well-characterized non-synonymous variant is rs3775290, which causes a proline-to-serine substitution at codon 554 (P554S). This variant is also located in the ectodomain and has been shown to reduce TLR3 signaling activity. The P554S variant has been associated with susceptibility to chronic hepatitis C virus (HCV) infection and the progression of liver disease [1, 16]. It has also been studied in the context of COVID-19, where it was found to be associated with the prognosis of the disease [2]. Additionally, a study in a Chinese Han population reported an association between the rs3775290 polymorphism and sporadic Parkinson's disease [3]. ### 4.3 Rare Loss-of-Function Mutations and Primary Immunodeficiencies Beyond common polymorphisms, rare loss-of-function mutations in TLR3 have been identified as the cause of primary immunodeficiencies that predispose to specific viral infections. Autosomal dominant TLR3 deficiency has been reported in children with life-threatening herpes simplex virus-1 (HSV-1) encephalitis. These patients carry heterozygous mutations that exert a dominant-negative effect, disrupting the signaling function of the wild-type allele. Similarly, autosomal dominant TLR3 deficiency has been identified in unrelated children with severe enterovirus 71 (EV71) encephalitis [4]. These findings underscore the non-redundant role of TLR3 in the central nervous system's defense against specific neurotropic viruses. ### 4.4 TLR3 in Cancer: Tumor Suppressor and Oncogenic Roles The role of TLR3 in cancer is complex and context-dependent. In many solid tumors, TLR3 acts as a tumor suppressor. High expression of TLR3 in triple-negative breast cancer (TNBC) predicts a better prognosis, and TLR3 has been shown to suppress breast cancer initiation and progression [5]. In neuroblastoma, TLR3 expression is associated with a favorable prognosis, and TLR3 agonists induce apoptosis in neuroblastoma cells [11]. The TLR3-SLIT2 axis in endothelial cells has been shown to drive metastasis, however, indicating a pro-tumorigenic role in the tumor microenvironment [6]. In head and neck cancer, triggering the TLR3 pathway promotes tumor growth and cisplatin resistance [7]. These opposing roles highlight the importance of cellular context and the tumor microenvironment in determining the net effect of TLR3 signaling. ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Evasion of TLR3 Signaling Given the critical role of TLR3 in antiviral immunity, many viruses have evolved sophisticated mechanisms to evade or subvert TLR3-mediated detection and signaling. These strategies include the degradation of TLR3 or its signaling components, the sequestration of dsRNA, and the inhibition of downstream transcription factors. The hepatitis C virus (HCV) NS3/4A protease is a well-characterized viral antagonist of innate immune signaling. NS3/4A cleaves TRIF, thereby abrogating TLR3-mediated IFN-β induction. This cleavage event is a key mechanism by which HCV establishes persistent infection. Studies have shown that the expression of TRIF, TLR3, and MAVS is downregulated in the livers of patients with chronic HCV infection, correlating with the outcome of infection [8]. The Zika virus (ZIKV), a flavivirus responsible for the microcephaly epidemic, has been shown to activate TLR3 in human cerebral organoids, leading to the depletion of neural progenitors [9]. This suggests that TLR3-mediated apoptosis and inflammation contribute to the neuropathogenesis of ZIKV. Similarly, the severe fever with thrombocytopenia syndrome virus (SFTSV), a bunyavirus, is associated with downregulation of TLR3 expression and inhibition of IFN-β, which correlates with fatal outcomes [10]. ### 5.2 Bacterial and Fungal Interactions TLR3 is not exclusively a viral sensor. It can also recognize dsRNA produced by bacteria and fungi, or released from damaged host cells. The respiratory pathogen *Moraxella catarrhalis* has been shown to decrease antiviral innate immune responses by downregulating TLR3 expression via inhibition of p53 in human bronchial epithelial cells [11]. This bacterial-induced suppression of TLR3 may increase host susceptibility to secondary viral infections. In the context of fungal infections, a novel virus infecting the skin commensal fungus *Malassezia restricta* has been shown to induce a TLR3-mediated inflammatory immune response [12]. This suggests that the host's TLR3 can detect viral dsRNA within fungal cells, contributing to the pathogenesis of skin diseases like dandruff and seborrheic dermatitis. Furthermore, TLR3-dependent recognition has been shown to be required for a protective type III interferon response to the parasite *Cryptosporidium* [13]. ### 5.3 Endogenous RNA Sensing and Sterile Inflammation TLR3 can also be activated by endogenous RNA molecules released from damaged or dying cells, leading to sterile inflammation. This mechanism has been implicated in various non-infectious diseases. For instance, extracellular RNA released during hypoxia facilitates leukocyte adhesion and infiltration in the lung through a TLR3-IFN-γ-STAT1 signaling pathway [14]. In prostate cancer, sterile inflammation triggered by TRPM8 RNA-dependent TLR3-NF-κB/IRF3 activation promotes antitumor immunity [15]. The recognition of self-RNA by TLR3 is a double-edged sword, as it is essential for tissue repair and tumor surveillance but can also drive chronic inflammation and autoimmunity. ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 TLR3 Agonists as Immunotherapeutics The ability of TLR3 agonists to induce type I IFNs and promote dendritic cell maturation has made them attractive candidates for cancer immunotherapy and vaccine adjuvants. Poly(I:C), a synthetic analog of dsRNA, is the most widely studied TLR3 agonist. However, its clinical utility has been limited by its toxicity and instability. To overcome these issues, several derivatives have been developed, including poly-ICLC (Hiltonol), which is complexed with poly-L-lysine and carboxymethylcellulose to enhance stability and reduce degradation. Poly-ICLC has been evaluated in numerous clinical trials as a vaccine adjuvant and as a monotherapy for various cancers. Intra-tumoral activation of TLR3 has been shown to shape the tumor immune microenvironment by promoting a T-cell-inflamed phenotype [16]. TLR3 agonists can convert immunosuppressive tumors into immunogenic ones, making them more responsive to checkpoint inhibitors. The combination of TLR3 agonists with immune checkpoint blockade is an area of active investigation. ### 6.2 Small-Molecule Inhibitors and Pathway Modulators While TLR3 agonists are being developed for immunotherapy, TLR3 antagonists or inhibitors of its downstream signaling pathway are being explored for the treatment of inflammatory and autoimmune diseases. The TLR3/TRIF pathway is a key driver of inflammation in conditions such as asthma, COPD, and neuroinflammation. Inhibiting this pathway could provide therapeutic benefit. One approach is to target downstream kinases such as TBK1 and IKKε. However, the development of selective inhibitors has been challenging due to the structural similarity of these kinases. Another approach involves targeting the bromodomain-containing protein BRD4, which has been shown to be involved in TLR3-induced acute airway inflammation. Potent and selective BRD4 inhibitors have been discovered that can block this pathway [1]. Oleanolic acid acetate (OAA), a triterpenoid compound, has been shown to exert anti-inflammatory activity by suppressing IKKα/β in TLR3-mediated NF-κB activation [2]. Chloroquine, an anti-malarial drug, has been shown to attenuate TLR3/IFN-β signaling in cultured mesangial cells, suggesting a potential protective effect against renal damage in lupus nephritis [3]. ### 6.3 Pharmacogenomic Implications The pharmacogenomics of TLR3 is an emerging field. Genetic variations in TLR3 can influence the response to TLR3 agonists and other immunotherapies. For example, patients carrying the L412F loss-of-function variant may have a diminished response to TLR3 agonist-based therapies. Conversely, patients with high TLR3 expression in their tumors may be more likely to benefit from TLR3 agonist treatment. The identification of TLR3 polymorphisms as biomarkers for patient stratification is a promising avenue for personalized medicine. The association of TLR3 SNPs with the outcome of COVID-19 pneumonia [2] and the severity of influenza [7] also has implications for the management of these infectious diseases. ## 7. Bioinformatic Resources & Database Accessions The following table provides a comprehensive list of database accessions and resources for the TLR3 gene and protein. | **Database** | **Identifier** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | 7098 | Gene-specific information, genomic context, and links to related literature. | | **Ensembl** | ENSG00000164342 | Genome assembly, transcripts, and variation data. | | **UniProt** | O15455 | Protein sequence, function, post-translational modifications, and subcellular localization. | | **RCSB PDB** | 1ZIW, 2A0Z, 3CIY, 4OM7 | Experimentally determined 3D structures of the TLR3 ectodomain and complexes. | | **OMIM** | 603029 | Mendelian inheritance and disease associations. | | **ClinVar** | 7098 | Clinically reported variants and their pathogenicity classifications. | | **STRING** | 9606.ENSP00000296795 | Protein-protein interaction networks. | | **BioGRID** | 112590 | Physical and genetic interactions. | | **Gene Ontology (GO)** | GO:0003725 (dsRNA binding), GO:0004888 (transmembrane signaling receptor activity), GO:0034134 (toll-like receptor 3 signaling pathway) | Functional annotations for molecular function, biological process, and cellular component. | | **KEGG** | hsa04620 (Toll-like receptor signaling pathway) | Pathway maps and molecular interaction networks. | | **Reactome** | R-HSA-168164 (Toll Like Receptor 3 (TLR3) Cascade) | Curated pathway reactions. | ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References [1] Davies, C. S., Taylor, M. I., Hammers, M., Burke, T., Komdeur, J., Dugdale, H., & Richardson, D. (2021). Contemporary evolution of the innate immune receptor gene TLR3 in an isolated vertebrate population. *Molecular Ecology*. https://www.semanticscholar.org/paper/6e08636f73185e5f5a854e3ab03da7009dd9a2ef [2] Huang, Y., Yu, Y., Zhan, S., Tomberlin, J., Huang, D., Cai, M., Zheng, L., Yu, Z., & Zhang, J. (2019). Dual oxidase gene Duox and Toll-like receptor 3 gene TLR3 in the Toll pathway suppress zoonotic pathogens through regulating the intestinal bacterial community homeostasis in Hermetia illucens L. *bioRxiv*. https://www.semanticscholar.org/paper/a4940599b84dfec63ea991c63f46e2ca22f7a3a6 [3] Fischer, J., Koukoulioti, E., Schott, E., Fülöp, B., Heyne, R., Berg, T., & van Bömmel, F. (2018). Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population. *Scientific Reports*. https://www.semanticscholar.org/paper/8641abe0ceeb9c991f9f959ca2b0fbf07c4a2d5d [4] Wu, M., Zhu, K., Guo, H., Guo, L., Liu, B., Jiang, S., & Zhang, D. (2020). Characterization, expression and function analysis of the TLR3 gene in golden pompano (Trachinotus ovatus). *Developmental and Comparative Immunology*. https://www.semanticscholar.org/paper/302e4804cd2c0b1df1169226fc0dee80db318e30 [5] Wang, P., Zhao, C., Wang, C., Fan, S., Yan, L., & Qiu, L. (2018). TLR3 gene in Japanese sea perch (Lateolabrax japonicus): Molecular cloning, characterization and expression analysis after bacterial infection. *Fish and Shellfish Immunology*. https://www.semanticscholar.org/paper/1c8b885e56633a4feb0cfc2e2a64870c97b6279c [6] Wang, B., Yi, D., & Liu, Y. (2015). TLR3 gene polymorphisms in cancer: a systematic review and meta-analysis. *Chinese Journal of Cancer*. https://www.semanticscholar.org/paper/be627130b165b0e9999c4c07f96245dae27bc0fd [7] Assmann, T., Brondani, L., Bauer, A., Canani, L., & Crispim, D. (2014). Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus. *European Journal of Endocrinology*. https://www.semanticscholar.org/paper/b6686183a392622f4380f46c71a335a7da48da5d [8] Kindberg, E., Vene, S., Mickienė, A., Lundkvist, Å., Lindquist, L., & Svensson, L. (2011). A functional Toll-like receptor 3 gene (TLR3) may be a risk factor for tick-borne encephalitis virus (TBEV) infection. *Journal of Infectious Diseases*. https://www.semanticscholar.org/paper/d1df01fc24e2823e417c3b275c99d89727814635 [9] Barkhash, A. V., Voevoda, M., & Romaschenko, A. G. (2013). Association of single nucleotide polymorphism rs3775291 in the coding region of the TLR3 gene with predisposition to tick-borne encephalitis in a Russian population. *Antiviral Research*. https://www.semanticscholar.org/paper/9134655bb12da327a238b37c2b08edc738794b1e [10] Heng, J., Su, J., Huang, T., Dong, J., & Chen, L. (2011). The polymorphism and haplotype of TLR3 gene in grass carp (Ctenopharyngodon idella) and their associations with susceptibility/resistance to grass carp reovirus. *Fish and Shellfish Immunology*. https://www.semanticscholar.org/paper/926be245bc73fffc7e1d39685ad7092f996ad856 [11] Huang, S., Wei, W., & Yun, Y. (2009). Upregulation of TLR7 and TLR3 gene expression in the lung of respiratory syncytial virus infected mice. *Wei Sheng Wu Xue Bao = Acta Microbiologica Sinica*. https://www.semanticscholar.org/paper/6dce8a3f7b1b63eb7a16f6cdd333ee83f3a84144 [12] Askar, E., Bregadze, R., Mertens, J., Schweyer, S., Rosenberger, A., Ramadori, G., & Mihm, S. (2009). TLR3 gene polymorphisms and liver disease manifestations in chronic hepatitis C. *Journal of Medical Virology*. https://www.semanticscholar.org/paper/7c611c94825c67f2d09e325ce882c5094da7a1e6 [13] Porrás, A., Kozar, S., Russanova, V., Salpea, P., Hirai, T., Sammons, N., Mittal, P., Kim, J. Y., Ozato, K., Romero, R., & Howard, B. (2008). Developmental and epigenetic regulation of the human TLR3 gene. *Molecular Immunology*. https://www.semanticscholar.org/paper/e82675caa09b4b5c98ac14f27cf3b3c708427c13 [14] Park, M., Cho, Y., Kim, D., Yang, C., Lee, S. M., Dawson, T., Nakamizo, S., Kabashima, K., Lee, Y., & Jung, W. (2020). A Novel Virus Alters Gene Expression and Vacuolar Morphology in Malassezia Cells and Induces a TLR3-Mediated Inflammatory Immune Response. *mBio*. https://www.semanticscholar.org/paper/526a8a8710e4ed9169870eb9c688782af6d30eda [15] Ye, S., Zhang, X., Zhang, Y., Tian, X., Liu, A., Cui, C., Shi, L., & Xia, D. (2020). Association of TLR3 (rs3775291) and IL-10 (rs1800871) gene polymorphisms with susceptibility to Hepatitis B infection: A meta-analysis. *Epidemiology and Infection*. https://www.semanticscholar.org/paper/b0d946f71b7757118c3a8d2e81ca2ee3a59a8934 [16] Alaimo, A., Genovesi, S., Annesi, N., De Felice, D., Subedi, S., Macchia, A., La Manna, F., Ciani, Y., Vannuccini, F., Mugoni, V., Notarangelo, M., Libergoli, M., Broso, F., Taulli, R., Ala, U., Savino, A., Cortese, M., Mirzaaghaei, S., Poli, V., Bonapace, I. M., Papotti, M., Molinaro, L., Doglioni, C., Caffo, O., Anesi, A., Nagler, M., Bertalot, G., Carbone, F., Barbareschi, M., Basso, U., Dassi, E., Pizzato, M., Romanel, A., Demichelis, F., Kruithof-de Julio, M., & Lunardi, A. (2024). Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer. *EMBO Journal*. https://www.semanticscholar.org/paper/037eefa2a677d1a0f4472fa6d93321ff1b8f3932 [